Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study
Martin Schiestl, Nivedita Roy, Michael Trieb, Joseph P. Park, Elena Guillen, Gillian Woollett, Elena Wolff-Holz
Springer Nature ·
2025-07-17
· DOI 10.1007/s40259-025-00733-1
The publisher did not provide an abstract — full text is available via the link below.
Martin Schiestl, Nivedita Roy, Michael Trieb, Joseph P. Park, Elena Guillen, Gillian Woollett et al. Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study. // BioDrugs. – 2025. – DOI: 10.1007/s40259-025-00733-1. – URL: https://doi.org/10.1007/s40259-025-00733-1
Martin Schiestl, Nivedita Roy, Michael Trieb, Joseph P. Park, Elena Guillen, Gillian Woollett, & Elena Wolff-Holz (2025). Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study. BioDrugs. https://doi.org/10.1007/s40259-025-00733-1
Martin Schiestl, et al. “Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study.” BioDrugs, 2025. doi:10.1007/s40259-025-00733-1.
@article{Schiestl2025,
title = {Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case Study},
author = {Schiestl, Martin and Roy, Nivedita and Trieb, Michael and Park, Joseph P. and Guillen, Elena and Woollett, Gillian and Wolff-Holz, Elena},
journal = {BioDrugs},
year = {2025},
doi = {10.1007/s40259-025-00733-1},
url = {https://doi.org/10.1007/s40259-025-00733-1}
}